About Lifecore Biomedical Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lifecore.com/
Frequently Asked Questions
What is the 52-week range for LFCR?
The 52-week high is $8.98 and the 52-week low is $3.63.
What is the P/E ratio for LFCR?
The P/E ratio data is currently unavailable.
What is the dividend yield for LFCR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -182.29%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -29.93%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.00.
Analyst Recommendation Trends
Wall Street analyst consensus for LFCR over the last few months:
Latest LFCR News
Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankruptcy
Major M&A deals include Valley National buys Bluevine, Roland Foods buys Savor Brands, Bloomberg completes Canoe deal.
Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing
https://www.sec.gov/Archives/edgar/data/1005286/000110465926111939/xslSCHEDULE_13D_X02/primary_doc.xml
Barrington Research Downgrades Lifecore Biomedical to Market Perform
Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Lifecore Biomedical: Bid Is Underwhelming
Lifecore Biomedical agreed to be acquired for $6.28/share in cash plus up to $3.39/share in CVRs. See why I rate LFCR stock a Hold right now.
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Let's take a look at the stocks that are in motion in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
William Blair Downgrades Lifecore Biomedical to Market Perform
William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CV
Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required "Conversion Amount" per Share in Cash at
Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business
Lifecore Biomedical is a Buy and is transitioning to a pure-play CDMO, with operational resets and capacity expansion. Read more on LFCR stock here.
Lifecore Biomedical to Participate at CPHI Global Conference
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy. Details regarding Lifecore’s participation are as follows: CPHI Global Conference Details: Lifecore leaders, including Mark DaFonseca, chief commercial of
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-04 | Legion Partners, L.P. I | +25,907 | - | - |
| 2026-06-04 | Johnson Paul Harold | +25,907 | - | - |
| 2026-06-04 | Antunes Humberto Calheiros | +25,907 | - | - |
| 2026-06-04 | Korenberg Matthew E | +25,907 | - | - |
| 2026-06-04 | Aryeh Jason | +25,907 | - | - |
| 2026-06-04 | Schechter Joshua | +25,907 | - | - |
| 2026-06-04 | HOUDE LOVAS KATRINA | +25,907 | - | - |
| 2026-06-04 | OBUS NELSON | +25,907 | - | - |
| 2026-05-20 | Josephs Paul | -40,413 | $4.57 | $184,687 |
| 2026-04-14 | Salus Thomas D. | -24,645 | $5.2 | $128,154 |
| 2026-03-02 | Salus Thomas D. | +30,000 | - | - |